Current radical mesothelioma treatments include chemotherapy, radiation therapy, surgical treatments and experimental therapies and drugs. Research News reports the limited success of current treatment options for mesothelioma.
Mesothelioma news from the research shows that traditional treatments viz. Single or multi-drug chemotherapy has a response rate of approximately 20%. Radiation, usually in combination with surgery or chemotherapy can be used to treat pain and relieveShrink tumors, breathing easier. However, irradiation can also cause serious side effects.
Efforts to fight against mesothelioma
Mesothelioma can take ten to sixty years to develop after the inhalation of respirable asbestos fibers, but mesothelioma progresses rapidly. Radical surgery such as mesothelioma treatments have had only limited success. Surgical treatments are tried extra-pleural pneumonectomy (EPP) and pleurectomy.
Treatment News indicates that inEPP over 15% of patients die soon after surgery. EPP is removal of the pleura, diaphragm, pericardium, part of the phrenic nerve and the entire affected lung tumor and is supported by chemotherapy or radiotherapy.
The pleurectomy treatments include removal of the pleura, without the whole lung. These treatments tend to be best in patients with lung expansion, good to accumulate fluid. In combination with radiotherapy is pleurectomy in the treatment of news reports have given rise to22-month survival rate at 50% and 24-month survival rate was 41% of cases in a 27-group of patients with mesothelioma of epithelial subtype.
Surgical treatment of mesothelioma have not been shown to offer significant advantages compared to the limited non-surgical treatments. Experimental drugs under review include treatments of Onconase, lovastatin, and a combination of endostatin and angiostatin.
The Mesothelioma Research Foundation of America is funding research to cure mesothelioma. The USC NorrisComprehensive Cancer Center in Los Angeles, has completed phase I clinical trials on a new mesothelioma treatment drug Veglin.
Phase II clinical trial of Veglin began in July 2004, opens up exciting possibilities for the treatment of mesothelioma victims.
Jon Butt publishes http://www.the-mesothelioma-guide.com With the Web, which is packed with mis information http://www.the-mesothelioma-guide.com support one of the leading free resource of mesothelioma,Counseling and legal assistance on alternative resources, natural supplements and much more. Help for you and your loved ones
No comments:
Post a Comment